<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MONOCLATE-P- antihemophilic factor human 
			 </strong><br>CSL Behring LLC<br></p></div>
<h1>Antihemophilic Factor (Human) <br> Monoclate-P<span class="Sup">®</span><br> Factor VIII:C Pasteurized <br> Monoclonal Antibody Purified</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DL"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">R<span class="Sub">x</span> only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Description"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Antihemophilic Factor (Human), Monoclate-P<span class="Sup">®</span>, Factor VIII:C Pasteurized, Monoclonal Antibody Purified, is a sterile, stable, lyophilized concentrate of Factor VIII:C with reduced amounts of VWF:Ag and purified of extraneous plasma-derived protein by use of affinity chromatography. A murine monoclonal antibody to VWF:Ag is used as an affinity ligand to first isolate the Factor VIII Complex. Factor VIII:C is then dissociated from VWF:Ag, recovered, formulated and provided as a sterile lyophilized powder.<span class="Sup">1,2,3</span>  The concentrate as formulated contains Albumin (Human) as a stabilizer, resulting in a concentrate with a specific activity between 4 and 10 units/mg of total protein. In the absence of this added Albumin (Human) stabilizer, specific activity has been determined to exceed 3000 units/mg of protein.<span class="Sup">4</span>  Monoclate-P<span class="Sup">®</span> has been prepared from pooled human plasma and is intended for use in therapy of classical <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span> (<span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">Hemophilia A</span>).</p>
<p>All Source Plasma used in the manufacture of this product was tested by FDA-licensed Nucleic Acid Testing (NAT) for HBV, HCV, and HIV-1 and found to be nonreactive (negative).</p>
<p>This concentrate has been pasteurized by heating at 60°C for 10 hours in aqueous solution form during its manufacture in order to further reduce the risk of viral transmission.<span class="Sup">5 </span>  However, no procedure has been shown to be totally effective in removing viral infectivity from coagulant factor concentrates (see <span class="Bold"><a href="#CP">CLINICAL PHARMACOLOGY</a></span> and <span class="Bold"><a href="#Warnings">WARNINGS</a></span>).</p>
<p>Monoclate-P<span class="Sup">®</span> is a highly purified preparation of Factor VIII:C. When stored as directed, it will maintain its labeled potency for the period indicated on the container and package labels.<span class="Sup">6,7</span></p>
<p>Upon reconstitution of the 250, 500 and 1000 IU concentrates, a clear, colorless solution is obtained, containing 50 to 150 times as much Factor VIII:C as does an equal volume of plasma.</p>
<p>Upon reconstitution of the 1500 IU concentrate, a clear, colorless solution is obtained, containing 120 to 180 times as much Factor VIII:C as does an equal volume of plasma.</p>
<p>Each vial contains the labeled amount of antihemophilic factor (AHF) activity as expressed in terms of International Units (IU) of antihemophilic activity. One unit of antihemophilic activity is equivalent to that quantity of AHF present in one mL of normal human plasma. When reconstituted as recommended, the resulting solution contains approximately 300 to 450 millimoles of sodium ions per liter and has 2 to 3 times the tonicity of saline. It contains approximately 2-5 millimoles of calcium ions per liter, contributed as calcium chloride, approximately 1 to 2% Albumin (Human), 0.8% mannitol, and 1.2 mM histidine. The pH is adjusted with hydrochloric acid and/or sodium hydroxide. Monoclate-P<span class="Sup">®</span> also contains trace amounts (≤50 ng per 100 IU of AHF) of the murine monoclonal antibody used in its purification (see <span class="Bold"><a href="#CP">CLINICAL PHARMACOLOGY</a></span>).</p>
<p>Monoclate-P<span class="Sup">®</span> is to be administered only intravenously.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="CP"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Factor VIII:C is the coagulant portion of the Factor VIII complex circulating in plasma. It is noncovalently associated with the von Willebrand protein responsible for von Willebrand factor activity. These two proteins have distinct biochemical and immunological properties and are under separate genetic control. Factor VIII:C acts as a cofactor for Factor IX to activate Factor X in the intrinsic pathway of blood coagulation.<span class="Sup">8</span>  <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">Hemophilia A</span>, a hereditary disorder of blood coagulation due to decreased levels of Factor VIII:C, results in profuse <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> into joints, muscles or internal organs as a result of a <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>. Monoclate-P<span class="Sup">®</span> provides an increase in plasma levels of AHF, thereby enabling temporary correction of <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">Hemophilia A</span> <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
<p>Clinical evaluation of Monoclate-P<span class="Sup">® </span>concentrate for its half-life characteristics in hemophilic patients showed it to be comparable to other commercially available Antihemophilic Factor (Human) concentrates. The mean half-life obtained from six patients was 17.5 hours with a mean recovery of 1.9 units/dl rise/U/kg.</p>
<p>The pasteurization process used in the manufacture of this concentrate has demonstrated <span class="Italics">in vitro</span> inactivation of human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV) and several model viruses. In two separate studies, HIV was reduced by ≥7.0 log<span class="Sub">10</span> to an undetectable level and by 10.5 log<span class="Sub">10</span>, respectively. In addition to HIV, studies were also performed using three lipid containing model viruses and one non-lipid, encapsulated model virus. Vesicular <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span> (VSV) was reduced by ≥6.79 log<span class="Sub">10</span> to undetectable, Sindbis was reduced by ≥6.48 log<span class="Sub">10</span> to undetectable and <span class="product-label-link" type="condition" conceptid="140633" conceptname="Vaccinia">Vaccinia</span> was reduced by ≥5.36 log<span class="Sub">10</span> to undetectable. Murine encephalomyocarditis (EMC), a non-lipid, encapsulated model virus, was reduced by ≥7.1 log<span class="Sub">10</span> to undetectable.</p>
<p>Evidence of the capability of the purification and preparative steps used in the production of Monoclate-P<span class="Sup">®</span> to reduce viral bioburden was obtained in studies involving the addition of known quantities of virus to cryoprecipitate. These studies were conducted using an earlier form of the concentrate which had not undergone liquid pasteurization (Antihemophilic Factor (Human),  Monoclate<span class="Sup">®</span>, Monoclonal Antibody Purified, Factor VIII:C, Heat-Treated). These studies provide evidence of the viral removal potential of the purification and preparative steps of the manufacturing process (exclusive of heat treatment) which are common to both concentrates. In one study, the viruses used were human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV), Sindbis virus, vesicular <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span> virus (VSV) and pseudorabies virus (PsRV). A comparison of the cumulative mean reductions for all viruses tested with the individual values obtained in each experiment indicates that the combined effects of the manufacturing steps, which purify the Factor VIII:C and prepare the concentrate in a final sterile container as a lyophilized powder, contribute viral reduction capabilities of approximately 5 to 6 logs. In a separate study, aluminum hydroxide treatment followed by antibody affinity chromatography reduced <span class="product-label-link" type="condition" conceptid="140633" conceptname="Vaccinia">vaccinia</span> virus infectivity by 4.81 logs. These studies indicate that the purification and preparative steps of the manufacturing process are capable of providing a non-specific, viral reduction of approximately 5 to 6 logs, independent of the pasteurization process.</p>
<p>Monoclate-P<span class="Sup">®</span> contains trace amounts of mouse protein<span class="Sup">9</span> (≤50 ng per 100 IU of AHF). In a study using an earlier form of the concentrate which had not undergone pasteurization (Monoclate<span class="Sup">®</span>), a number of patients seronegative for Anti-HIV-1 were monitored to determine whether they would develop antibody or experience adverse reactions as a result of repeated exposure. These patients were treated on multiple occasions. Pre-study serum measurements of 27 patients for human anti-mouse IgG showed that, prior to treatment, 6 of them had either detectable antibody to mouse proteins or cross-reactive proteins. These patients continued to demonstrate similar or lower antibody levels during the study. Of the remaining 21 patients, 6 were shown to have low antibody levels on one or more occasions. In no case was observance of low antibody level associated with an anamnestic response or with any clinical adverse reaction. Patients were observed for time periods ranging from 2 to 30 months.</p>
<p>The viral safety of Monoclate-P<span class="Sup">®</span> has been evaluated in two open-label studies using patients (aged 1 day to 20 years) with moderate to severe <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span> previously unexposed to blood or blood products. Thirty patients received Monoclate-P<span class="Sup">®</span> therapy for 5 to 34 months as necessary according to the normal practices of the treatment center. These patients were followed for serum ALT elevations and a range of viral serologies. Six patients received another blood product prior to or during the study. Twenty-four patients were evaluable for assessment of viral safety of Monoclate-P<span class="Sup">®</span>. No patients seroconverted to HIV, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> nonA/nonB, or <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B. Factor VIII:C inhibitors developed in 7 patients (23%) with 3 being high (&gt;10 BU) titer.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Monoclate-P<span class="Sup">®</span> is indicated for treatment of classical <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span> (<span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">Hemophilia A</span>). Affected individuals frequently require therapy following minor <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accidents</span>. Surgery, when required in such individuals, must be preceded by temporary corrections of the clotting abnormality. Surgical prophylaxis in severe AHF deficiency can be accomplished with an appropriately-dosed pre-surgical IV bolus of Monoclate-P<span class="Sup">®</span> followed by intermittent maintenance doses (see <span class="Bold"><a href="#DA">DOSAGE AND ADMINISTRATION</a></span>).</p>
<p>Monoclate-P<span class="Sup">®</span> is not effective in controlling the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> of patients with von Willebrand's disease.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to mouse protein is a contraindication to Monoclate-P<span class="Sup">®</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Warnings"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Monoclate-P<span class="Sup">®</span> is made from human blood. Products made from human plasma may contain infectious agents, such as viruses, that can cause disease. Because Monoclate-P<span class="Sup">®</span> is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> and inactivating and/or removing certain viruses during manufacture (see <span class="Bold"><a href="#Description">DESCRIPTION</a></span> section for viral reduction measures). The manufacturing procedure for Monoclate-P<span class="Sup">®</span> includes processing steps designed to reduce further the risk of viral transmission. Stringent procedures utilized at plasma collection centers, plasma testing laboratories, and fractionation facilities are designed to reduce the risk of viral transmission. The primary viral reduction step of the Monoclate-P<span class="Sup">®</span> manufacturing process is the heat treatment of the purified, stabilized aqueous solution at 60°C for 10 hours. In addition, the purification procedure (several precipitation steps) used in the manufacture of Monoclate-P<span class="Sup">®</span> also provides viral reduction capacity. Despite these measures, such products may still potentially contain human pathogenic agents, including those not yet known or identified. Thus the risk of transmission of infectious agents can not be totally eliminated. Any <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> thought by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to CSL Behring at 1-866-915-6958 (in the U.S. or Canada).</p>
<p>Individuals who receive infusions of blood or plasma products may develop signs and/or symptoms of some <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (see <span class="Bold"><a href="#PreIFP">Information For Patients</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Most Antihemophilic Factor (Human) concentrates contain naturally occurring blood group specific antibodies. However, the processing of Monoclate-P<span class="Sup">®</span> significantly reduces the presence of blood group specific antibodies in the final product. Nevertheless, when large or frequently repeated doses of product are needed, patients should be monitored by means of hematocrit and direct Coombs tests for signs of progressive <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2>Formation of Antibodies to Mouse Protein</h2>
<p class="First">Although no <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been observed, because Monoclate-P<span class="Sup">®</span> contains trace amounts of mouse protein (≤50 ng per 100 IU of AHF), the possibility exists that patients treated with Monoclate-P<span class="Sup">®</span> may develop <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the mouse proteins.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="PreIFP"></a><a name="section-7.3"></a><p></p>
<h2>Information For Patients</h2>
<p class="First">Patients should be informed of the early signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">generalized urticaria</span>, tightness of the chest, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, and should be advised to discontinue use of the concentrate and contact their physician if these symptoms occur.</p>
<p>Some viruses, such as parvovirus B19 or <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> A, are particularly difficult to remove or inactivate at this time. Parvovirus B19 most seriously affects pregnant women, or immune-compromised individuals.</p>
<p>Although the overwhelming number of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> A and parvovirus B19 cases are community acquired, there have been reports of these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> associated with the use of some plasma-derived products. Therefore, physicians should be alert to the potential symptoms of parvovirus B19 and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> A <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and inform patients under their supervision receiving plasma derived products to report potential symptoms promptly.</p>
<p>Symptoms of parvovirus B19 include <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> and <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">runny nose</span> followed two weeks later by a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>. Evidence of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> A may include several days to weeks of poor appetite, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, and low-grade <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> followed by <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the belly. Dark urine and a yellowed complexion are also common symptoms. Patients should be encouraged to consult their physicians if such symptoms occur.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.4"></a><p></p>
<h2>Pregnancy Category C</h2>
<p class="First">Animal reproduction studies have not been conducted with Monoclate-P<span class="Sup">®</span>. It is also not known whether Monoclate-P<span class="Sup">®</span> can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Monoclate-P<span class="Sup">®</span> should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.5"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The safety and effectiveness of Monoclate-P<span class="Sup">®</span> for the treatment of <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span> has been demonstrated in 33 pediatric patients. As in adults, pediatric patients should be dosed based upon weight (see <span class="Bold"><a href="#DA">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.6"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of Monoclate-P<span class="Sup">®</span> did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Dosing should be appropriate to the clinical situation.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Products of this type are known to cause <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, mild <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> at the infusion site. In some cases, inhibitors of FVIII may occur.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DA"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Monoclate-P<span class="Sup">®</span> is for intravenous administration only. As a general rule 1 unit of AHF activity per kg will increase the circulating AHF level by 2%.<span class="Sup">10</span>  The following formula<span class="Sup">10 </span>provides a guide of dosage calculations for both adult and pediatric patients:</p>
<table class="Noautorules" width="75%">
<col align="center" valign="middle" width="22%">
<col align="center" valign="middle" width="5%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="5%">
<col align="center" valign="middle" width="28%">
<col align="center" valign="middle" width="5%">
<col align="left" valign="middle" width="15%">
<tbody class="Headless">
<tr>
<td align="center">Number of AHF</td>
<td align="center">=</td>
<td align="center">Body weight</td>
<td align="center">×</td>
<td align="center">desired Factor VIII</td>
<td align="center">×</td>
<td align="left">0.5</td>
</tr>
<tr>
<td align="center">IU Required</td>
<td align="center"></td>
<td align="center">(in kg)</td>
<td align="center"></td>
<td align="center">increase (% normal)</td>
<td align="center"></td>
<td align="left"></td>
</tr>
</tbody>
</table>
<p>Although dosage must be individualized according to the needs of the patient (weight, severity of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, presence of inhibitors), the following general dosages are suggested.<span class="Sup">11</span></p>
<ol>
<li>MILD <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">HEMORRHAGES</span> - Minor hemorrhagic episodes will generally subside with a single infusion if a level of 30% or more is attained.</li>
<li>MODERATE <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">HEMORRHAGE</span> AND MINOR SURGERY - For more serious <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span> and minor surgical procedures, the patient's Factor VIII level should be raised to 30-50% of normal, which usually requires an initial dose of 15-25 IU per kg. If further therapy is required a maintenance dose is 10-15 IU per kg every 8-12 hours.</li>
<li>SEVERE <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">HEMORRHAGE</span> - In <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span> near vital organs (neck, throat, subperitoneal) it may be desirable to raise the Factor VIII level to 80-100% of normal which can be achieved with an initial dose of 40-50 IU per kg and a maintenance dose of 20-25 IU per kg every 8-12 hours.</li>
<li>MAJOR SURGERY - For surgical procedures a dose of AHF sufficient to achieve a level 80-100% of normal should be given an hour prior to surgery. A second dose, half the size of the priming dose, should be given five hours after the first dose. Factor VIII levels should be maintained at a daily minimum of at least 30% for a period of 10-14 days postoperatively. Close laboratory control to maintain AHF plasma levels deemed appropriate to maintain hemostasis is recommended.</li>
</ol>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Reconstitution</h2>
<ol>
<li>Warm both the diluent and Monoclate-P<span class="Sup">®</span> in unopened vials to room temperature [not above 37°C (98°F)].</li>
<li>Remove the caps from both vials to expose the central portions of the rubber stoppers.</li>
<li>Treat the surface of the rubber stoppers with antiseptic solution and allow them to dry.</li>
<li>Using aseptic technique, insert one end of the double-end needle into the rubber stopper of the diluent vial. Invert the diluent vial and insert the other end of the double-end needle into the rubber stopper of the Monoclate-P<span class="Sup">®</span> vial. Direct the diluent, which will be drawn in by vacuum, over the entire surface of the Monoclate-P<span class="Sup">®</span> cake. (In order to assure transfer of all the diluent, adjust the position of the tip of the needle in the diluent vial to the inside edge of the diluent stopper.)  Rotate the vial to ensure complete wetting of the cake during the transfer process.</li>
<li>Remove the diluent vial to release the vacuum, then remove the double-end needle, from the Monoclate-P<span class="Sup">®</span> vial.</li>
<li>Gently swirl the vial until the powder is dissolved and the solution is ready for administration. The concentrate routinely and easily reconstitutes within one minute. To assure <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span>, Monoclate-P<span class="Sup">®</span> should be administered within three hours after reconstitution.</li>
<li>Parenteral drug preparations should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2>Administration</h2>
<dl>
<dt> </dt>
<dd>
<span class="Underline">CAUTION</span>:  This kit contains two devices, a stainless steel 5 micron filter needle, individually labeled as a 5 micron filter needle and contained in a separate <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack, and an all plastic 5 micron vented filter spike which is supplied with the four-item administration components <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack, either of which may be used to withdraw the reconstituted product for administration. The withdrawal directions specific for each of these alternate devices must be followed <span class="Underline">exactly</span> for whichever device is chosen for use as described below. Product loss or inability to withdraw product will result if the improper instructions are followed.</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2.1"></a><p></p>
<dl>
<dt>A.</dt>
<dd> Administration using the stainless steel filter needle for withdrawal<br><p class="First">(This item is individually packaged in a separate, labeled <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack.)</p>
<p><span class="Bold">Intravenous Injection</span></p>
<p>Plastic disposable syringes are recommended with Monoclate-P<span class="Sup">®</span> solution. The ground glass surfaces of all-glass syringes tend to stick with solutions of this type.</p>
<dl>
<dt>1.</dt>
<dd>Using aseptic technique, attach the filter needle to a sterile disposable syringe.</dd>
<dt>2.</dt>
<dd>Draw air into the syringe equal to or greater than the contents of the vial.</dd>
<dt>3.</dt>
<dd>Insert the filter needle into the stopper of the Monoclate-P<span class="Sup">®</span> vial, invert the vial, position the filter needle above the level of the liquid and inject all of the air into the vial.</dd>
<dt>4.</dt>
<dd>Pull the filter needle back down below the level of the liquid until the tip is at the inside edge of the stopper.</dd>
<dt>5.</dt>
<dd>Withdraw the reconstituted solution into the syringe being careful to always keep the tip of the needle below the level of the liquid.</dd>
<dt> </dt>
<dd>
<span class="Underline">CAUTION</span>:      Failure to inject air into the vial, or allowing air to pass through the filter needle while filling the syringe with reconstituted solution, may cause the needle to clog.</dd>
<dt>6.</dt>
<dd>Discard the filter needle. Perform venipuncture using the enclosed winged needle with microbore tubing. Attach the syringe to the luer end of the tubing.</dd>
<dt> </dt>
<dd>
<span class="Underline">CAUTION</span>:      Use of other winged needles without microbore tubing, although compatible with the concentrate, will result in a larger retention of solution within the winged infusion set.</dd>
<dt class="Bold">7.</dt>
<dd><span class="Bold">Administer solution intravenously at a rate (approximately 2 mL/minute) comfortable to the patient.</span></dd>
</dl>
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2.2"></a><p></p>
<dl>
<dt>B.</dt>
<dd>Administration using the all plastic vented filter spike for withdrawal<br><p class="First">(This spike is supplied in the four-item Administration Components pack.)</p>
<p><span class="Bold">Intravenous Injection</span></p>
<p>Plastic disposable syringes are recommended with Monoclate-P<span class="Sup">®</span> solution. The ground glass surfaces of all-glass syringes tend to stick with solutions of this type.</p>
<dl>
<dt>1.</dt>
<dd>Using aseptic technique, attach the vented filter spike to a sterile disposable syringe.</dd>
<dt> </dt>
<dd>
<span class="Underline">CAUTION</span>: DO NOT INJECT AIR INTO THE MONOCLATE-P<span class="Sup">®</span> VIAL. The self-venting feature of the vented filter spike precludes the need to inject air in order to facilitate withdrawal of the reconstituted solution. The injection of air could cause partial product loss through the vent filter.</dd>
<dt> </dt>
<dd>
<span class="Underline">CAUTION</span>: The use of other, non-vented filter needles or spikes without the proper procedure may result in an air lock and prevent the complete transfer of the concentrate.</dd>
<dt>2.</dt>
<dd>Insert the vented filter spike into the stopper of the Monoclate-P<span class="Sup">®</span> vial, invert the vial, and position the filter spike so that the orifice is at the inside edge of the stopper.</dd>
<dt>3.</dt>
<dd>Withdraw the reconstituted solution into the syringe.</dd>
<dt>4.</dt>
<dd>Discard the filter spike. Perform venipuncture using the enclosed winged needle with microbore tubing. Attach the syringe to the luer end of the tubing.</dd>
<dt> </dt>
<dd>
<span class="Underline">CAUTION</span>: Use of other winged needles without microbore tubing, although compatible with the concentrate, will result in a larger retention of solution within the winged infusion set.</dd>
<dt class="Bold">5.</dt>
<dd><span class="Bold"> Administer solution intravenously at a rate (approximately 2 mL/minute) comfortable to the patient.</span></dd>
</dl>
</dd>
</dl>
</div>
</div>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-10"></a><p></p>
<h1>STORAGE</h1>
<p class="First">When stored at refrigerator temperature, 2-8°C (36-46°F), Monoclate-P<span class="Sup">®</span> is stable for the period indicated by the expiration date on its label. Within this period, Monoclate-P<span class="Sup">®</span> may be stored at room temperature not to exceed 25°C (77°F), for up to 6 months. </p>
<p>Avoid freezing which may damage container for the diluent.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Monoclate-P<span class="Sup">®</span> is supplied in a single dose vial with Sterile Water for Injection, USP, double-ended needle for reconstitution, vented filter spike for withdrawal, filter needle for withdrawal, winged infusion set and alcohol swabs. Factor VIII activity in IU is stated on the label of each vial.</p>
<p>Each product package consists of the following:</p>
<table width="80%">
<col align="center" valign="bottom" width="30%">
<col align="left" valign="top" width="40%">
<col align="center" valign="bottom" width="30%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center" valign="top">NDC Number</th>
<th class="Rrule" align="center">Component</th>
<th class="Rrule" align="center" valign="top">Approximate FVIII Activity (IU)</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">0053-7631-02</td>
<td class="Rrule" align="left">Carton (kit) containing one vial of Monoclate-P<span class="Sup">®</span> [NDC 0053-7641-01], one 2.5 mL vial of Sterile Water for Injection, USP (diluent) [NDC 0053-7653-02], one double-ended needle for reconstitution, one vented filter spike for withdrawal, one filter needle for withdrawal, one winged infusion set, and alcohol swabs.</td>
<td class="Rrule" align="center">250 (LOW)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">0053-7632-02</td>
<td class="Rrule" align="left">Carton (kit) containing one vial of Monoclate-P<span class="Sup">®</span> [NDC 0053-7642-01], one 5 mL vial of Sterile Water for Injection, USP (diluent) [NDC 0053-7653-05], one double-ended needle for reconstitution, one vented filter spike for withdrawal, one filter needle for withdrawal, one winged infusion set, and alcohol swabs.</td>
<td class="Rrule" align="center">500 (MID)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">0053-7633-02</td>
<td class="Rrule" align="left">Carton (kit) containing one vial of Monoclate-P<span class="Sup">®</span> [NDC 0053-7643-01], one 10 mL vial of Sterile Water for Injection, USP (diluent) [NDC 0053-7653-10], one double-ended needle for reconstitution, one vented filter spike for withdrawal, one filter needle for withdrawal, one winged infusion set, and alcohol swabs.</td>
<td class="Rrule" align="center">1000 (HIGH)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">0053-7634-02</td>
<td class="Rrule" align="left">Carton (kit) containing one vial of Monoclate-P<span class="Sup">®</span> [NDC 0053-7644-01], one 10 mL vial of Sterile Water for Injection, USP (diluent) [NDC 0053-7653-10], one double-ended needle for reconstitution, one vented filter spike for withdrawal, one filter needle for withdrawal, one winged infusion set, and alcohol swabs.</td>
<td class="Rrule" align="center">1500 (SUPER HIGH)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-12"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>W. Terry, A. Schreiber, C. Tarr, M. Hrinda, W. Curry and F. Feldman, Human Factor VIII:C Produced Using Monoclonal Antibodies, in <span class="Italics">Research in Clinic and Laboratory</span>, Vol. XVI, (#1), 202 (1986) from the XVIIth International Congress of the World Federation of <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">Hemophilia</span>.</li>
<li>A. B. Schreiber, The Preclinical Characterization of Monoclate Factor VIII C Antihemophilic Factor Human, <span class="Italics">Semin Hematol</span> 25 (2 Suppl. 1), 1988, pp. 27-32.</li>
<li>E. Berntorp and I.M. Nilsson, Biochemical Properties of Human Factor VIII C Monoclate Purified Using Monoclonal Antibody to VWF, <span class="Italics">Thromb Res</span> O (Suppl. 7), 1987, p. 60, from the Satellite Symposia of the XIth International Congress on <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span> and Haemostasis, Brussels, Belgium, July 11, 1987.</li>
<li>S. Chandra, C.C. Huang, R.L. Weeks, K. Beatty and F. Feldman, Purity of a Factor VIII:C Preparation (Monoclate) Manufactured by Monoclonal Immunoaffinity Chromatography Technique, from the XVIII International Congress of the World Federation of <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">Hemophilia</span>, May 1988.</li>
<li>B. Spire, D. Dormont, F. Barre-Sinousii, L. Montagnier, and J.C. Chermann, Inactivation of <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">Lymphadenopathy</span> Associated Virus by Heat, Gamma Rays, and Ultraviolet Light, <span class="Italics">Lancet</span>, Jan. 26, 1985, p. 188.</li>
<li>F. Feldman, R. Kleszynski, L. Ho, R. Kling, S. Chandra and C.C. Huang, Validation of Coagulation Test Methods for Evaluation of Monoclate (Factor VIII:C) Potencies, from the XVIII International Congress of the World Federation of <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">Hemophilia</span>, May 1988.</li>
<li>S. Chandra, C.C. Huang, L. Ho, R. Kling, R.L. Weeks and F. Feldman, Studies on the Stability of Factor VIII:C (Monoclate) in Lyophilized and Solution Form, from the XVIII International Congress of the World Federation of <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">Hemophilia</span>, May 1988.</li>
<li>L.W. Hoyer, The Factor VIII Complex:  Structure and Function, <span class="Italics">Blood</span> 58 (1981), p.1.</li>
<li>F. Feldman, S. Chandra, R. Kleszynski, C.C. Huang and R.L. Weeks, Measurement of Murine Protein Levels in Monoclonal Antibody Purified Coagulation Factor, from the XVIII International Congress of the World Federation of <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">Hemophilia</span>, May 1988.</li>
<li>C.F. Abilgaard, J.V. Simone, J.J. Corrigan, et al., Treatment of <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">Hemophilia</span> with Glycine - Precipitated Factor VIII, <span class="Italics">New Eng J Med</span>, 275 (1966), p. 471.</li>
<li>C.K. Kasper, Hematologic Care, <span class="Italics">Comprehensive Management of <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">Hemophilia</span></span>, ed. Boone, D.C., Philadelphia, F.A. Davis Co., (1976) pp. 2-20.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<h1>BIBLIOGRAPHY</h1>
<p class="First">Hershman, R.J., Naconti, S.B., and Shulman, N.R. <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> Treatment of <span class="product-label-link" type="condition" conceptid="4120609" conceptname="Factor VIII deficiency">Factor VIII Deficiency</span>. <span class="Italics">Blood</span> 35, (1970), p. 189.</p>
<p>Kasper, C.K. Dietrich, S.I. and Rapaport, S.K. <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">Hemophilia</span> Prophylaxis in Factor VIII Concentrate. <span class="Italics">Arch Int Med</span> 125, (1970), p. 1004.</p>
<p>Biggs, R. ed. The Treatment of <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">Hemophilia A</span> and B and von Willebrands Disease. Oxford: Blackwell, 1978.</p>
<p>Fulcher, C.A., Zimmerman, T.S., Characterization of the Human Factor VIII Procoagulant Protein With A Heterologous Precipitating Antibody. <span class="Italics">Proc Natl Acad Sci</span> 79 (1982), pp. 1648-1652.</p>
<p>Levine, P.H., Factor VIII C Purified from Plasma Via Monoclonal Antibodies Human Studies. <span class="Italics">Semin Hematol</span> 25 (2 Suppl. 1), 1988, pp. 38-41.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14"></a><p></p>
<p class="First">Manufactured by:<br><span class="Bold">CSL Behring LLC</span><br>Kankakee, IL 60901 USA<br>US License No. 1767</p>
<p>Revised February, 2014<br>12810-08</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 250 IU Kit Carton</h1>
<p class="First"><span class="Bold">NDC 0053-7631-02</span><br>One vial with diluent</p>
<p><span class="Bold">LOW</span></p>
<p><span class="Bold">Antihemophilic Factor<br>(Human)<br>Monoclate-P</span><span class="Sup">®</span></p>
<p><span class="Bold">Factor VIII:C Pasteurized<br>Monoclonal Antibody Purified</span></p>
<p><span class="Bold">For Intravenous Administration Only.<br>Rx only</span></p>
<p>Storage: Monoclate-P<span class="Sup">®</span> stored in a refrigerator at 2-8°C (36-46°F) is <br>                  stable for the period indicated by the expiration date on the label. <br>                  Within this period Monoclate-P<span class="Sup">®</span> may be stored at room temperature <br>                  not to exceed 25°C (77°F), for up to 6 months. Avoid freezing.</p>
<p>Manufactured by:<br><span class="Bold">CSL Behring LLC</span><br>Kankakee, IL 60901 USA<br>                     US License No. 1767</p>
<p><span class="Bold">CSL Behring</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 250 IU Kit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d9c17023-cbff-4d95-8f44-ef842d59d938&amp;name=monoclate-01.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 500 IU Kit Carton</h1>
<p class="First"><span class="Bold">NDC 0053-7632-02</span><br>One vial with diluent</p>
<p><span class="Bold">MID</span></p>
<p><span class="Bold">Antihemophilic Factor<br>(Human)<br>Monoclate-P</span><span class="Sup">®</span></p>
<p><span class="Bold">Factor VIII:C Pasteurized<br>Monoclonal Antibody Purified</span></p>
<p><span class="Bold">For Intravenous Administration Only.<br>Rx only</span></p>
<p>Storage: Monoclate-P<span class="Sup">®</span> stored in a refrigerator at 2-8°C (36-46°F) is <br>                  stable for the period indicated by the expiration date on the label. <br>                  Within this period Monoclate-P<span class="Sup">®</span> may be stored at room temperature <br>                  not to exceed 25°C (77°F), for up to 6 months. Avoid freezing.</p>
<p>Manufactured by:<br><span class="Bold">CSL Behring LLC</span><br>Kankakee, IL 60901 USA<br>                     US License No. 1767</p>
<p><span class="Bold">CSL Behring</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 500 IU Kit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d9c17023-cbff-4d95-8f44-ef842d59d938&amp;name=monoclate-02.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 1000 IU Kit Carton</h1>
<p class="First"><span class="Bold">NDC 0053-7633-02</span><br>One vial with diluent</p>
<p><span class="Bold">HIGH</span></p>
<p><span class="Bold">Antihemophilic Factor<br>(Human)<br>Monoclate-P</span><span class="Sup">®</span></p>
<p><span class="Bold">Factor VIII:C Pasteurized<br>Monoclonal Antibody Purified</span></p>
<p><span class="Bold">For Intravenous Administration Only.<br>Rx only</span></p>
<p>Storage: Monoclate-P<span class="Sup">®</span> stored in a refrigerator at 2-8°C (36-46°F) <br>                  is stable for the period indicated by the expiration date on the <br>                  label. Within this period Monoclate-P<span class="Sup">®</span> may be stored at room <br>                  temperature not to exceed 25°C (77°F), for up to 6 months. <br> Avoid freezing.</p>
<p>Manufactured by:<br><span class="Bold">CSL Behring LLC</span><br>Kankakee, IL 60901 USA<br>                     US License No. 1767</p>
<p><span class="Bold">CSL Behring</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 1000 IU Kit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d9c17023-cbff-4d95-8f44-ef842d59d938&amp;name=monoclate-03.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 1500 IU Kit Carton</h1>
<p class="First"><span class="Bold">NDC 0053-7634-02</span><br>One vial with diluent</p>
<p><span class="Bold">SUPER HIGH</span></p>
<p><span class="Bold">Antihemophilic Factor<br>(Human)<br>Monoclate-P</span><span class="Sup">®</span></p>
<p><span class="Bold">Factor VIII:C Pasteurized<br>Monoclonal Antibody Purified</span></p>
<p><span class="Bold">For Intravenous Administration Only.<br>Rx only</span></p>
<p>Storage: Monoclate-P<span class="Sup">®</span> stored in a refrigerator at 2-8°C (36-46°F) is <br>                  stable for the period indicated by the expiration date on the label. <br>                  Within this period Monoclate-P<span class="Sup">®</span> may be stored at room temperature <br>                  not to exceed 25°C (77°F), for up to 6 months. Avoid freezing.</p>
<p>Manufactured by:<br><span class="Bold">CSL Behring LLC</span><br>Kankakee, IL 60901 USA<br>                     US License No. 1767</p>
<p><span class="Bold">CSL Behring</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 1500 IU Kit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d9c17023-cbff-4d95-8f44-ef842d59d938&amp;name=monoclate-04.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MONOCLATE-P 		
					</strong><br><span class="contentTableReg">antihemophilic factor human kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PLASMA DERIVATIVE</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0053-7631</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0053-7631-02</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, SINGLE-DOSE </td>
<td class="formItem">2.5 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL, SINGLE-DOSE </td>
<td class="formItem">2.5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>MONOCLATE-P 		
					</strong><br><span class="contentTableReg">antihemophilic factor human injection, powder, lyophilized, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0053-7641</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ANTIHEMOPHILIC FACTOR HUMAN</strong> (ANTIHEMOPHILIC FACTOR HUMAN) </td>
<td class="formItem">ANTIHEMOPHILIC FACTOR HUMAN</td>
<td class="formItem">250 [iU]  in 2.5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>albumin (human)</strong></td>
<td class="formItem">50 mg  in 2.5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Mannitol</strong></td>
<td class="formItem">8 mg  in 2.5 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Histidine</strong></td>
<td class="formItem">0.0012 mmol  in 2.5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0053-7641-01</td>
<td class="formItem">2.5 mL in 1 VIAL, SINGLE-DOSE; Combination Product Type = C102839</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103953</td>
<td class="formItem">05/30/1990</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>DILUENT 		
					</strong><br><span class="contentTableReg">water injection</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2.5 mL in 1 VIAL, SINGLE-DOSE; Combination Product Type = C102839</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103953</td>
<td class="formItem">05/30/1990</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103953</td>
<td class="formItem">05/30/1990</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MONOCLATE-P 		
					</strong><br><span class="contentTableReg">antihemophilic factor human kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PLASMA DERIVATIVE</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0053-7632</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0053-7632-02</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, SINGLE-DOSE </td>
<td class="formItem">5 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL, SINGLE-DOSE </td>
<td class="formItem">5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>MONOCLATE-P 		
					</strong><br><span class="contentTableReg">antihemophilic factor human injection, powder, lyophilized, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0053-7642</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ANTIHEMOPHILIC FACTOR HUMAN</strong> (ANTIHEMOPHILIC FACTOR HUMAN) </td>
<td class="formItem">ANTIHEMOPHILIC FACTOR HUMAN</td>
<td class="formItem">500 [iU]  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>albumin (human)</strong></td>
<td class="formItem">100 mg  in 5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Mannitol</strong></td>
<td class="formItem">8 mg  in 5 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Histidine</strong></td>
<td class="formItem">0.0012 mmol  in 5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0053-7642-01</td>
<td class="formItem">5 mL in 1 VIAL, SINGLE-DOSE; Combination Product Type = C102839</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103953</td>
<td class="formItem">05/30/1990</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>DILUENT 		
					</strong><br><span class="contentTableReg">water injection</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 VIAL, SINGLE-DOSE; Combination Product Type = C102839</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103953</td>
<td class="formItem">05/30/1990</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103953</td>
<td class="formItem">05/30/1990</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MONOCLATE-P 		
					</strong><br><span class="contentTableReg">antihemophilic factor human kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PLASMA DERIVATIVE</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0053-7633</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0053-7633-02</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, SINGLE-DOSE </td>
<td class="formItem">10 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL, SINGLE-DOSE </td>
<td class="formItem">10 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>MONOCLATE-P 		
					</strong><br><span class="contentTableReg">antihemophilic factor human injection, powder, lyophilized, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0053-7643</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ANTIHEMOPHILIC FACTOR HUMAN</strong> (ANTIHEMOPHILIC FACTOR HUMAN) </td>
<td class="formItem">ANTIHEMOPHILIC FACTOR HUMAN</td>
<td class="formItem">1000 [iU]  in 10 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>albumin (human)</strong></td>
<td class="formItem">200 mg  in 10 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Mannitol</strong></td>
<td class="formItem">8 mg  in 10 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Histidine</strong></td>
<td class="formItem">0.0012 mmol  in 10 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0053-7643-01</td>
<td class="formItem">10 mL in 1 VIAL, SINGLE-DOSE; Combination Product Type = C102839</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103953</td>
<td class="formItem">05/30/1990</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>DILUENT 		
					</strong><br><span class="contentTableReg">water injection</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL, SINGLE-DOSE; Combination Product Type = C102839</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103953</td>
<td class="formItem">05/30/1990</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103953</td>
<td class="formItem">05/30/1990</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MONOCLATE-P 		
					</strong><br><span class="contentTableReg">antihemophilic factor human kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PLASMA DERIVATIVE</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0053-7634</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0053-7634-02</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, SINGLE-DOSE </td>
<td class="formItem">10 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL, SINGLE-DOSE </td>
<td class="formItem">10 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>MONOCLATE-P 		
					</strong><br><span class="contentTableReg">antihemophilic factor human injection, powder, lyophilized, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0053-7644</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ANTIHEMOPHILIC FACTOR HUMAN</strong> (ANTIHEMOPHILIC FACTOR HUMAN) </td>
<td class="formItem">ANTIHEMOPHILIC FACTOR HUMAN</td>
<td class="formItem">1500 [iU]  in 10 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>albumin (human)</strong></td>
<td class="formItem">200 mg  in 10 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Mannitol</strong></td>
<td class="formItem">8 mg  in 10 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Histidine</strong></td>
<td class="formItem">0.0012 mmol  in 10 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0053-7644-01</td>
<td class="formItem">10 mL in 1 VIAL, SINGLE-DOSE; Combination Product Type = C102839</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103953</td>
<td class="formItem">03/04/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>DILUENT 		
					</strong><br><span class="contentTableReg">water injection</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL, SINGLE-DOSE; Combination Product Type = C102839</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103953</td>
<td class="formItem">03/04/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103953</td>
<td class="formItem">03/04/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>CSL Behring LLC
							(058268293)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">CSL Behring LLC</td>
<td class="formItem"></td>
<td class="formItem">058268293</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>aef1f9f9-aece-492d-9c09-8099ea79c0cc</div>
<div>Set id: d9c17023-cbff-4d95-8f44-ef842d59d938</div>
<div>Version: 7</div>
<div>Effective Time: 20141006</div>
</div>
</div> <div class="DistributorName">CSL Behring LLC</div></p>
</body></html>
